drugset / Trial / NCT01221545

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics After High Single Ascending Oral Doses of AZD1656 in T2DM Patients

NCT01221545

Phase 1 Completed 24 enrolled AstraZeneca
RandomizedSingle-groupSingle-blindBasic science

Summary

The purpose of this study is to investigate safety and tolerability after high Single Ascending Oral Doses of AZD1656.

Timeline

Start
2010-10
Primary completion
2011-01
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD1656 Small molecule Oral